For Inherent Anticipation, How Many Is Too Many? | McDermott Will & Emery

The US Court of Appeals for the Federal Circuit affirmed a Patent Trial & Appeal Board (Board) decision that prior art disclosing a class of 957 salts could not inherently anticipate...

Related Keywords

,Mylan Pharms ,Us Court ,Merck Sharp Dohme Corp ,Mcdermott Will ,Federal Circuit ,Patent Trial ,Appeal Board ,Dohme Corp ,Patents Appeals ,